Attomarker
Multiplex blood-testing technology for clinicians, patients and researchers seeking rapid biomarker diagnostics
Highlights
- New on EvolcAdded 2026-11-08
About Attomarker
Attomarker develops a multiplex diagnostic platform that measures multiple biomarkers from a finger-prick blood sample. Its tests provide quantitative results for applications including Long COVID, infection, fertility, liver health and allergies.
The company serves patients, clinicians, researchers and commercial or clinical partners. It was founded in 2008 as a spin-out from the University of Exeter and is based in Exeter, United Kingdom. Its team includes product, research and international development leadership.
Product: A nanophotonic multiplex testing platform and blood tests that quantify multiple biomarkers, including its COVID Antibody Spectrum Test.
Jobs at Attomarker
Leadership
- Andrew Shaw · CEO & FounderSource: company website
- Andrew Vincent · Chief Marketing OfficerSource: company website
More health & medtech companies
audika.co.uk
Hearing tests, hearing aids and ongoing audiology care for people with hearing loss across the UKNew on EvolcAudiological Science
Independent hearing aid supply and audiology services for patients across the UKNew on EvolcAugmentia
Native desktop app helping UK GP practices manage chronic care, QOF and CQC compliance, and clinical codingYoung companyNew on EvolcAutonomy Care Group
Residential and domiciliary care for adults and young people with learning disabilities and complex needs in EnglandNew on EvolcSalary transparentAveamedix
Clinical visualisation products in development for dental and surgical cliniciansYoung companyNew on EvolcAver Generics
Wholesale supplier of generic medicines and pharmaceutical products to pharmacies across the UKNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinitialization/configuration expression
- Integration code on pageinitialization/configuration expression
- Integration code on pageinitialization/configuration expression
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Marketing & advertising
- Meta PixelMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinitialization/configuration expression
- Integration code on pageinitialization/configuration expression
- Integration code on pageinitialization/configuration expression
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.